医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hanmi Selects Medidata to Power Drug Development with Cloud Technology

2016年07月06日 AM06:30
このエントリーをはてなブックマークに追加


 

NEW YORK

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research, announced today that it has signed a multi-year enterprise deal with Hanmi Pharmaceutical, one of South Korea’s leading drug makers.

A Medidata customer since 2013, the Seoul-based pharmaceutical company is expanding its technology partnership with Medidata, becoming the first Korean company to incorporate the Medidata Clinical Cloud® into all clinical trials across its drug development programs.

“Our expanded partnership with Medidata is a key example of the aggressive investments we’re making in R&D to grow our business globally and accelerate drug development, so that we can more quickly and efficiently develop innovative new treatments for patients,” said Ji-Woong Son, vice president of Hanmi Pharmaceutical. “We are very pleased to collaborate with Medidata, the global leader in clinical trial technology. By leveraging their cloud platform, analytics and deep life sciences industry expertise, we can better ensure productivity and accuracy in our research efforts and the high quality of our clinical data.”

In the last five years, Hanmi has more than doubled its investment in R&D—from 84 billion won in 2011 to 187 billion won in 2015—to accelerate R&D innovation and establish itself as a global market leader. The company is focused on developing novel therapies to advance care in diabetes, obesity, oncology and auto-immunology.

Hanmi has been using Medidata’s unified electronic data capture, management and reporting tool (Medidata Rave®) and medical coding capabilities (Medidata Coder®) in a number of its studies since 2013. The company will now expand its use of both solutions, as well as leverage Medidata’s Trial Assurance offering, across its entire clinical development program. A comprehensive solution which evaluates the quality of clinical and lab data, Medidata Trial Assurance calls upon powerful statistical algorithms to automatically mine the clinical database of each study—identifying anomalies, outliers, potential fraud and misconduct, and procedural issues to mitigate risk and optimize trial results.

“As new medical advances in Korea make their way to global markets, there’s been an increasing demand for data standardization and more efficient clinical trials across the Asia-Pacific region,” said Edwin Ng, Medidata’s vice president of APeJ (Asia Pacific except Japan). “Our cloud technology platform is meeting this demand and powering innovation for Hanmi. We’re excited to expand our partnership and look forward to supporting them as they develop novel biologics, chemical entities and drugs for patients on a global scale.”

Connect with Medidata:

About Hanmi Pharmaceutical Co., Ltd

Since its establishment in 1973, Hanmi Pharmaceutical has become Korea’s very first global pharmaceutical company through Korean R&D strategy starting from synthesis technology development continues to generic, IMD/FDC and innovative new drugs. Hanmi has entered 6 license agreements worth a combined 8 trillion won with global big pharma including Sanofi, Boehringer Ingelheim, Janssen, etc. in 2015, also has been collaborating with MSD, Sanofi-Aventis Korea, etc. on fixed dose combination drugs related business. Furthermore, Hanmi has various strategic partnerships with multinational companies and biotechs through Open Innovation strategy. Currently, Hanmi is conducting global clinical trials for developing biologics based on proprietary platform technology LAPSCOVERY and anti-cancer new drugs, etc.

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. We are committed to advancing the competitive and scientific goals of our life sciences customers worldwide: more than 600 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. Our industry-leading technology platform, the Medidata Clinical Cloud®, is the primary technology solution powering clinical trials for 17 of the world’s top 25 global pharmaceutical companies, bringing new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160705006091/en/

CONTACT

Medidata
Investor:
Hulus Alpay,
+1-212-419-1025
halpay@mdsol.com
or
Media
Americas
& EMEA
:
Nicole Pariser, +1-212-659-1069
npariser@mdsol.com
or
Media
APAC:
Da
Jeong Chong, +82-2-2015-7715
dchong@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 国际纳米技术展览暨研讨会——2017纳米科技展将为您带来尖端技术与材料的最新资讯,令超智能社会触手可及
  • Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies
  • “nano tech 2017 国際ナノテクノロジー総合展・技術会議”開催、超スマート社会の実現に貢献する最先端技術・材料の最新情報を発信!
  • nano tech 2017, the International Nanotechnology Exhibition & Conference, Brings You the Latest Information on the Cutting Edge Technologies and Materials Making the Super Smart Society a Reality
  • Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer